{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T19:08:15Z","timestamp":1769886495977,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"DOI":"10.7759\/cureus.102672","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:55:27Z","timestamp":1769831727000},"source":"Crossref","is-referenced-by-count":0,"title":["Immunogenic Tumor Cell Death Induced by Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer: An Immunohistochemical Analysis"],"prefix":"10.7759","author":[{"given":"Tatsuki","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Owari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel RL","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018, 68:7-30. 10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman HB","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, et al.. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003, 349:859-66. 10.1056\/NEJMoa022148","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","unstructured":"Neoadjuvant chemotherapy in invasive bladder cancer. update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005, 48:202-5; discussion 205-6. 10.1016\/j.eururo.2005.04.006","journal-title":"Eur Urol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy O","year":"2018","unstructured":"Fahmy O, Khairul-Asri MG, Schubert T, et al.. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 2018, 36:43-53. 10.1016\/j.urolonc.2017.10.002","journal-title":"Urol Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.08.024","article-title":"Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer: analysis of the GETUG\/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses","volume":"79","author":"Pfister C","year":"2021","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, et al.. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer: analysis of the GETUG\/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol. 2021, 79:214-21. 10.1016\/j.eururo.2020.08.024","journal-title":"Eur Urol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.01.115","article-title":"A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)","volume":"181","author":"deVere White RW","year":"2009","unstructured":"deVere White RW, Lara PN Jr, Goldman B, et al.. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009, 181:2476-81. 10.1016\/j.juro.2009.01.115","journal-title":"J Urol"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan D","year":"2000","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000, 100:57-70.","journal-title":"Cell"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018","volume":"25","author":"Galluzzi L","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, et al.. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018, 25:486-541. 10.1038\/s41418-017-0012-4","journal-title":"Cell Death Differ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00588","article-title":"Molecular and translational classifications of DAMPs in immunogenic cell death","volume":"6","author":"Garg AD","year":"2015","unstructured":"Garg AD, Galluzzi L, Apetoh L, et al.. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 2015, 6:588. 10.3389\/fimmu.2015.00588","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko DV","year":"2012","unstructured":"Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012, 12:860-75.","journal-title":"Nat Rev Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2017.05.024","article-title":"Cytokines in immunogenic cell death: applications for cancer immunotherapy","volume":"97","author":"Showalter A","year":"2017","unstructured":"Showalter A, Limaye A, Oyer JL, Igarashi R, Kittipatarin C, Copik AJ, Khaled AR. Cytokines in immunogenic cell death: applications for cancer immunotherapy. Cytokine. 2017, 97:123-32. 10.1016\/j.cyto.2017.05.024","journal-title":"Cytokine"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-821310-0.00008-5","article-title":"Revisiting immunogenic cell death to improve treatment response in cancer","author":"Shakfa N","year":"2021","unstructured":"Shakfa N, Siemens DR, Koti M. Revisiting immunogenic cell death to improve treatment response in cancer. Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance. Elsevier, Amsterdam; 2021. 65-90. 10.1016\/B978-0-12-821310-0.00008-5"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/iju.12749","article-title":"Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: long-term follow-up experience at a single institute","volume":"22","author":"Miyake M","year":"2015","unstructured":"Miyake M, Gotoh D, Shimada K, et al.. Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: long-term follow-up experience at a single institute. Int J Urol. 2015, 22:541-7. 10.1111\/iju.12749","journal-title":"Int J Urol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2016.02.012","article-title":"Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy","volume":"34","author":"Morizawa Y","year":"2016","unstructured":"Morizawa Y, Miyake M, Shimada K, et al.. Neutrophil-to-lymphocyte ratio as a detection marker of tumor recurrence in patients with muscle-invasive bladder cancer after radical cystectomy. Urol Oncol. 2016, 34:257.e11-7. 10.1016\/j.urolonc.2016.02.012","journal-title":"Urol Oncol"},{"key":"ref16","article-title":"Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer","volume":"50","author":"McClelland RA","year":"1990","unstructured":"McClelland RA, Finlay P, Walker KJ, Nicholson D, Robertson JF, Blamey RW, Nicholson RI. Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res. 1990, 50:3545-50.","journal-title":"Cancer Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3892\/or.2017.6097","article-title":"Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma","volume":"39","author":"Aoto K","year":"2018","unstructured":"Aoto K, Mimura K, Okayama H, et al.. Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma. Oncol Rep. 2018, 39:151-9. 10.3892\/or.2017.6097","journal-title":"Oncol Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10413","article-title":"HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review","volume":"7","author":"Wu T","year":"2016","unstructured":"Wu T, Zhang W, Yang G, Li H, Chen Q, Song R, Zhao L. HMGB1 overexpression as a prognostic factor for survival in cancer: a meta-analysis and systematic review. Oncotarget. 2016, 7:50417-27. 10.18632\/oncotarget.10413","journal-title":"Oncotarget"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23040","article-title":"Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer","volume":"106","author":"Yang GL","year":"2012","unstructured":"Yang GL, Zhang LH, Bo JJ, et al.. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012, 106:57-61. 10.1002\/jso.23040","journal-title":"J Surg Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/446093-immunogenic-tumor-cell-death-induced-by-neoadjuvant-chemotherapy-in-patients-with-muscle-invasive-bladder-cancer-an-immunohistochemical-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:55:28Z","timestamp":1769831728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/446093-immunogenic-tumor-cell-death-induced-by-neoadjuvant-chemotherapy-in-patients-with-muscle-invasive-bladder-cancer-an-immunohistochemical-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.102672","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}